Stellate Ganglion Block to Reduce Hot Flushes

Rijnstate Hospital76 enrolled

Overview

To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure

Hot flushes are the most common symptom of menopause for which postmenopausal (PMP) women seek medical help, in 20% of PMP women hot flushes can persist for up to 15 years. A possible treatment for hot flushes is stellate ganglion block (SGB), used as a means to interrupt parts of the sympathetic nervous system involved in temperature regulation. Single centre randomized double blind placebo controlled intervention study Study period of 6 months in which patients will fill out on set time points 5 questionnaires regarding quality of life and keep a diary on hot flush frequency and severity during1 week on the same time points. Study population: Postmenopausal women aged 30-70 years old with no other causes of flushing present. Intervention (if applicable) Intervention: Stellate ganglion block versus sham procedure Follow up with questionnaires during 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hot Flash Stellate Ganglion Block Postmenopausal Hot Flushes

Interventions

Bupivacaine blockPROCEDURE

stellate ganglion bupivacaine injection

Placebo ganglion blockPROCEDURE

stellate ganglion sodium chloride injection

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Female * Age: 30-70 years * Mean daily flush frequency of 10 or more and a hot flush score of 15 or more * Absence of any non-menopausal cause of flushing * Post-menopause amenorrhea for more than 1 year in healthy postmenopausal women * In case of breast cancer or ovariectomy induced menopause: ovariectomy for \> 6 months. Adjuvant therapy with estrogen-receptor blocker or an aromatase inhibitor. Exclusion Criteria: * Use of medication that affects flushing:oestrogens, progestogens, clonidine, naloxone, paroxetine, fluoxetine, venlafaxine, gabapentin, luteïniserend hormone releasing hormones receptor antagonist * Receiving chemotherapy of radiotherapy * Active psychiatric disease * Active concurrent disease * Allergic reactions against local anesthetics of the 'amide' type or contrast media.

Locations (1)

Rijnstate hospital

Arnhem, Netherlands

Outcomes

Primary Outcomes

Hot Flush score

Hot flush score as measured by a hot flush diary in which for each hot flush the severity is noted for one week. Severity of every flush is given on a 1-4 scale (1 is mild, 2 medium, 3 severe, and 4 is very severe)

Time frame: Baseline, 4, and 8 weeks

Secondary Outcomes

Quality of sleep

Pittsburgh Sleep Quality Index: developed to discriminate between good and poor sleep quality. It consists of 19 individual items, creating seven components of sleep (sleep onset latency, sleep duration, sleep efficiency, sleep quality, sleep disturbances,medication, and day-time dysfunction). Each of those seven components is scored from 0 to 3. The sum of the individual scores forms the global score (0-21) of the PSQI. Lower global scores denote high sleep quality, whereas a score greater than 5 is considered poor sleep quality

Time frame: Baseline, 4, and 8 weeks

Sleepiness

Epworth Sleepiness Scale. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The reference range of 'normal' ESS scores is zero to 10.

Time frame: Baseline, 4, and 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.